Lipidomics Reveals Serum Specific Lipid Alterations in Diabetic Nephropathy

• Published in: Frontiers in endocrinology (Lausanne) 2021-12, Vol.12, p.781417-781417
• Main Authors: Xu, Tingting, Xu, Xiaoyan, Zhang, Lu, Zhang, Ke, Wei, Qiong, Zhu, Lin, Yu, Ying, Xiao, Liangxiang, Lin, Lili, Qian, Wenjuan, Wang, Jue, Ke, Mengying, An, Xiaofei, Liu, Shijia
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers - blood; Cohort Studies; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetic Nephropathies - blood; Diabetic Nephropathies - diagnosis; diabetic nephropathy; Endocrinology; Female; Humans; Lipidomics; Lipidomics - methods; Lipids - blood; LPE(16:0); Male; Middle Aged; PE(16:0/20:2); TAG54:2-FA18:1; Young Adult
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2021.781417

In diabetes mellitus (DM), disorders of glucose and lipid metabolism are significant causes of the onset and progression of diabetic nephropathy (DN). However, the exact roles of specific lipid molecules in the pathogenesis of DN remain unclear. This study recruited 577 participants, including healthy controls (HCs), type-2 DM (2-DM) patients, and DN patients, from the clinic. Serum samples were collected under fasting conditions. Liquid chromatography-mass spectrometry-based lipidomics methods were used to explore the lipid changes in the serum and identify potential lipid biomarkers for the diagnosis of DN. Lipidomics revealed that the combination of lysophosphatidylethanolamine (LPE) (16:0) and triacylglycerol (TAG) 54:2-FA18:1 was a biomarker panel for predicting DN. The receiver operating characteristic analysis showed that the panel had a sensitivity of 89.1% and 73.4% with a specificity of 88.1% and 76.7% for discriminating patients with DN from HCs and 2-DM patients. Then, we divided the DN patients in the validation cohort into microalbuminuria (diabetic nephropathy at an early stage, DNE) and macroalbuminuria (diabetic nephropathy at an advanced stage, DNA) groups and found that LPE(16:0), phosphatidylethanolamine (PE) (16:0/20:2), and TAG54:2-FA18:1 were tightly associated with the stages of DN. The sensitivity of the biomarker panel to distinguish between patients with DNE and 2-DM, DNA, and DNE patients was 65.6% and 85.9%, and the specificity was 76.7% and 75.0%, respectively. Our experiment showed that the combination of LPE(16:0), PE(16:0/20:2), and TAG54:2-FA18:1 exhibits excellent performance in the diagnosis of DN.